Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Dougados

Showing results (301-310 of 600) with videos related to

Pageof 60
Sort By:
Joint Bone Spine|November 29, 2011
Clinical characteristics of anterior chest wall pain in spondyloarthritis: an analysis of 275 patientsMuriel Elhai, Simon Paternotte, Vincent Burki, et al.
RMD Open|October 30, 2025
Evaluation of spondyloarthritis-specific health utility based on ASAS health index (U-ASAS-HI) among the disease subtypes: an ancillary analysis from the ASAS-PerSpA studyOmar-Javier Calixto, Xenofon Baraliakos, Wilson Bautista-Molano, et al.
Annals of the Rheumatic Diseases|December 10, 2017
Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA studyElena Nikiphorou, Désirée van der Heijde, Sam Norton, et al.
RMD Open|March 24, 2023
Characterisation of gut microbiota composition in patients with axial spondyloarthritis and its modulation by TNF inhibitor treatmentMarie Vallier, Béatrice Segurens, Elise Larsonneur, et al.
RMD Open|March 1, 2024
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA studyMaxime Dougados, Audrey Lardy-Cléaud, Emilie Desfleurs, et al.
Clinical and Experimental Rheumatology|February 21, 2012
Prevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patientsJudith Payet, Laure Gossec, Simon Paternotte, et al.
Annals of the Rheumatic Diseases|June 1, 2010
A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trialMaxime Dougados, Bernard Combe, Jürgen Braun, et al.
RMD Open|October 27, 2017
Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritisPierre-Antoine Juge, Steven Gazal, Arnaud Constantin, et al.
Annals of the Rheumatic Diseases|October 4, 2017
Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritisWalter P Maksymowych, Stephanie Wichuk, Maxime Dougados, et al.
Arthritis Research & Therapy|November 29, 2015
Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activityJanet Pope, Clifton O Bingham, Roy M Fleischmann, et al.
Pageof 60

Showing results (301-310 of 600) with videos related to

Sort By:
Pageof 60
Joint Bone Spine|November 29, 2011
Clinical characteristics of anterior chest wall pain in spondyloarthritis: an analysis of 275 patientsMuriel Elhai, Simon Paternotte, Vincent Burki, et al.
RMD Open|October 30, 2025
Evaluation of spondyloarthritis-specific health utility based on ASAS health index (U-ASAS-HI) among the disease subtypes: an ancillary analysis from the ASAS-PerSpA studyOmar-Javier Calixto, Xenofon Baraliakos, Wilson Bautista-Molano, et al.
Annals of the Rheumatic Diseases|December 10, 2017
Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA studyElena Nikiphorou, Désirée van der Heijde, Sam Norton, et al.
RMD Open|March 24, 2023
Characterisation of gut microbiota composition in patients with axial spondyloarthritis and its modulation by TNF inhibitor treatmentMarie Vallier, Béatrice Segurens, Elise Larsonneur, et al.
RMD Open|March 1, 2024
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA studyMaxime Dougados, Audrey Lardy-Cléaud, Emilie Desfleurs, et al.
Clinical and Experimental Rheumatology|February 21, 2012
Prevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patientsJudith Payet, Laure Gossec, Simon Paternotte, et al.
Annals of the Rheumatic Diseases|June 1, 2010
A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trialMaxime Dougados, Bernard Combe, Jürgen Braun, et al.
RMD Open|October 27, 2017
Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritisPierre-Antoine Juge, Steven Gazal, Arnaud Constantin, et al.
Annals of the Rheumatic Diseases|October 4, 2017
Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritisWalter P Maksymowych, Stephanie Wichuk, Maxime Dougados, et al.
Arthritis Research & Therapy|November 29, 2015
Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activityJanet Pope, Clifton O Bingham, Roy M Fleischmann, et al.
Pageof 60